All these data indicated that the combinational use of melatonin and BRAF‐targeting agent dabrafenib has the potential to become a novel approach in the treatment of anaplastic thyroid cancer. This evidence concerns the gene BRAF and thyroid gland undifferentiated (anaplastic) carcinoma.